A Strategic Cooperation Agreement Was Reached To Further Deepen Its Presence in The GLP-1 Field

Deepening our presence in the GLP-1 field, BoYun Biotech and Xiu Shi Biopharma have reached a strategic cooperation agreement.

On August 30th, Tianjin Boyun Purification Equipment Materials Technology Co., Ltd. ("Boyun Biotech") and Xiu Shi Biopharma (Nantong) Co., Ltd. ("Xiu Shi Biopharma") held a strategic cooperation signing ceremony, marking the beginning of a new dimension of cooperation. After reaching the agreement, the focus will be on the GLP-1 field, fully leveraging the strengths and characteristics of both parties, strengthening information exchange and resource integration, and creating a win-win, sustainable strategic partnership.

About this strategic cooperation

Wang Qunjie - Chairman of Boyun Biotech

As a leader in comprehensive solutions for separation and purification, Boyun Biotech is pleased to explore the GLP-1 field in depth with Xiu Shi Biopharma. The global GLP-1 market will continue to grow rapidly in the future, presenting enormous industrial opportunities domestically. Boyun Biotech will leverage its advantages in separation materials, purification equipment, and process development, joining hands with Xiu Shi Biopharma to stay at the forefront of the industry.

Wu Yinsong - Chairman of Xiu Shi Biopharma

Xiu Shi Biopharma is very honored to have reached a deep strategic cooperation with Boyun Biotech. Together, we will accelerate the establishment of the GLP-1 product core technology platform, realize the application and promotion of more efficient separation and purification technology for biosynthetic peptides, and jointly promote innovation and development in the peptide industry.

About Boyun Biotech

Boyun Biotech - belongs to the Aegeboya Group, is a brand of industrial chromatography products under the AegeBOya Group. Committed to providing customers with overall solutions for industrial separation and purification based on chromatography and specific adsorption, the products are completely independent research and development, production, and provide customers with supporting process technology services.

The company establishes the grand vision of "absorbing all things in the world and storing up to pure essence", adheres to the core mission of "leading the industry with technology" and promoting the "intelligent manufacturing" of medicine with innovation, and provides the whole process chain overall solution for the service objects. Independent research and development and production of Bonnasil high-purity silica gel matrix industrial chromatography separation filler, with its unique hole optimization technology, surface treatment technology, with uniform pore size, uniform particle size, high sample load, high pressure resistance and other excellent properties, is the first choice for small and medium-sized molecular separation and purification of core separation materials in the field of domestic substitution. At the same time, we have many new products of special chromatographic separation and adsorption materials, such as polar, alkali-resistant, hydrophilic and other organic bonded silica gel, protein restriction, core-shell, magnetic solid phase extraction and other chromatographic media; Specific adsorption materials such as trace metals, endotoxins, organic toxins and biological samples phospholipid proteins have reached the level of international mainstream products in terms of quality and stability, and have significant advantages in price. From laboratory to industrial automation purification equipment complete. Intelligent, automated industrial chromatography separation and purification equipment with online monitoring, online liquid distribution, online solvent recovery and other innovative design, fully meet the pharmaceutical industry standards.

About Xiu Shi Biopharma

Xiu Shi Biopharma was established in 2020, with a core team composed of technical experts in pharmaceutical engineering, fermentation engineering, protein engineering, and other related fields. Leveraging rich practical experience in the field of biomanufacturing, Xiu Shi Biopharma provides industry partners with innovative and highly attractive solutions for the biosynthesis of peptide drugs. Currently, Xiu Shi Biopharma's unique innovative biosynthesis strategy has been successfully validated on various short peptides and complex cyclic peptides at a large scale, offering production capacity and cost advantages that surpass traditional biological and chemical synthesis methods. This has led to collaboration orders from numerous downstream well-known pharmaceutical companies and CDMO enterprises. Xiu Shi Biopharma is committed to helping partners stay ahead in the discovery and production process of peptide drugs through innovative biosynthesis technology.